Ularitide

Updated: 2026-09-12

Overview

Ularitide is a synthetic analog of urodilatin, a peptide hormone produced in the kidneys. It shares structural and functional similarities with atrial natriuretic peptide (ANP) but exhibits enhanced stability and receptor selectivity. Developed for cardiovascular research, it targets natriuretic peptide receptors to modulate fluid balance and vascular tone. As an investigational drug, ularitide has been studied in phase II/III clinical trials for acute decompensated heart failure. Its mechanism involves reducing preload and afterload while promoting sodium excretion, offering potential advantages over conventional therapies like nitroglycerin or nesiritide.

Physical and Chemical Properties

Ularitide is a polypeptide with a defined amino acid sequence, typically formulated as a sterile lyophilized powder for reconstitution. Its stability depends on proper storage, with degradation risks from light, heat, or humidity. The compound is water-soluble, facilitating intravenous administration in clinical settings. While exact molecular details may vary by manufacturer, ularitide's bioactivity relies on its tertiary structure, which mimics endogenous urodilatin. Analytical methods like HPLC or mass spectrometry are used to verify purity, often exceeding 95% for research applications.

Main Applications

The primary application of ularitide is in cardiovascular therapeutics, specifically for acute heart failure syndromes. It has shown promise in improving dyspnea and reducing pulmonary capillary wedge pressure (PCWP) in clinical studies. Unlike loop diuretics, it offers a balanced approach by combining vasodilation with renal sodium excretion. Research also explores its role in cardiorenal syndrome management, where conventional therapies face limitations. Off-label investigations include potential use in hypertensive crises or perioperative hemodynamic optimization, though these remain experimental.

Safety and Storage

Ularitide requires careful handling due to its potent pharmacological effects. Clinical preparations must follow aseptic techniques to prevent contamination. The lyophilized form should be stored frozen (-20°C or below) and protected from light; reconstituted solutions are typically stable for ≤24 hours at 2-8°C. Adverse effects may include symptomatic hypotension, especially in volume-depleted patients. Monitoring of blood pressure, renal function, and electrolytes is essential during administration. Occupational exposure risks are low with proper PPE, but accidental injection requires immediate medical attention.

B2B Procurement Guide

Procuring ularitide demands verification of supplier qualifications, including GMP certification for clinical-grade material. Key considerations include batch-specific certificates of analysis (CoA), stability data, and regulatory documentation (e.g., DMF references). Lead times can be extended due to specialized production requirements. Bulk purchases for research may qualify for tiered pricing, but costs remain high given the compound's niche status. Alternatives like nesiritide might be considered for certain applications, though receptor affinity profiles differ. Always confirm import/export regulations, as peptide therapeutics often face strict controls.